Compare LYFT Inc (LYFT) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LYFT Inc vs Organon & Co. Common Stock — how do they compare? LYFT Inc trades at $16.36 (market cap $6.20B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: LYFT Inc is the larger of the two by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while LYFT Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold LYFT Inc for 48 Days and Organon & Co. Common Stock for 0 Days on average.
| LYFT | OGN | |
|---|---|---|
Market Cap | $6.20B | $3.62B |
Volume | 12,306,511 | 2,892,999 |
Sector | Technology | Health |
52-Week High | $24.57 | $13.81 |
52-Week Low | $12.65 | $5.70 |
Typical Hold Time | 48 Days | 0 Days |
Enterprise Value | $5.67B | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lyft (LYFT) trades at $16.48, up 2.3% with a bullish technical signal. The stock shows strong fundamentals with a P/E of 2.38 and net income margin of 42.32%. Recent developments include European expansion and a $272.5M legal settlement. Cash flow improved significantly to $891M in 2025 from negative levels in prior years, while revenue grew to $6.32B.
Outlook remains positive with analyst consensus target of $18.07, though mixed earnings performance and regulatory risks persist. The stock offers value with low valuation multiples but faces competition and execution challenges in international markets. Recent technical indicators show overbought conditions near resistance at $17.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About LYFT Inc
Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
